コンピュータシミュレーションを用いた結核対策政策の評価
T F Brewer1, S J Heymann, G A Colditz
1Channing Laboratory, Brigham and Women's Hospital, Boston, Mass 02115, USA.
JAMA
|December 18, 1996
まとめ
改善された結核 (TB) 治療と予防療法とBCGワクチン接種を組み合わせることは,国家的な結核撲滅目標を達成するために不可欠です. HIV患者に対する標的型予防療法により,結核の症例と死亡が著しく減少しています.
科学分野:
- 公衆衛生は公衆衛生である.
- エピデミオロジー エピデミオロジー
- 数学的モデリング
背景:
- 国家目標は,米国における結核 (TB) 撲滅を目指しています.
- 現在の結核対策戦略では,より効果的な評価方法が必要です.
研究 の 目的:
- 結核対策戦略のための効果的な方法を開発し,評価する.
- 様々な結核政策の変更が結核撲滅目標に与える影響を評価する.
主な方法:
- 半マルコフモデルを用いて,米国の人口を年齢層と臨床状態に分割した.
- このモデルは,5つの政策変更を評価した:予防療法と治療のカバー/有効性の向上,BCGワクチン接種.
- 政策は個別に,そして組み合わせて分析されました.
主要な成果:
- BCGワクチン接種だけで,結核の症例を17%減らせ,死亡率を11%減らせることができる.
- HIV患者に対する標的型予防療法では,HIV関連結核の症例と死亡率が14%から20%減少することが示されました.
- 改善された治療,予防療法,BCGワクチン接種を組み合わせた戦略により,結核の症例が47%減少し,死亡率は50%減少しました.
結論:
- 結核治療の普及率や有効性を改善するだけでは,国の結核撲滅目標を達成できません.
- 結核の撲滅を達成するには,改善された現在のプログラムと,標的型予防療法とBCGワクチン接種を組み合わせた多面的なアプローチが必要です.
関連する概念動画
01:16Critical Region, Critical Values and Significance Level
The critical region, critical value, and significance level are interdependent concepts crucial in hypothesis testing.
In hypothesis testing, a sample statistic is converted to a test statistic using z, t, or chi-square distribution. A critical region is an area under the curve in probability distributions demarcated by the critical value. When the test statistic falls in this region, it suggests that the null hypothesis must be rejected. As this region contains all those values of the test...
In hypothesis testing, a sample statistic is converted to a test statistic using z, t, or chi-square distribution. A critical region is an area under the curve in probability distributions demarcated by the critical value. When the test statistic falls in this region, it suggests that the null hypothesis must be rejected. As this region contains all those values of the test...
01:04Significance Testing: Overview
Significance testing is a set of statistical methods used to test whether a claim about a parameter is valid. In analytical chemistry, significance testing is used primarily to determine whether the difference between two values comes from determinate or random errors. The effect of a particular change in the measurement protocol, analyst, or sample itself can cause a deviation from the expected result. In the case of a suspected deviation/outlier, we need to be able to confirm mathematically...
01:26Pharmacokinetic Models: Comparison and Selection Criterion
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
01:20Drug Product Performance: In Vitro–In Vivo Correlation
In pharmaceutical development, it's crucial to establish a predictive in vitro–in vivo correlation (IVIVC) for two or more formulations to gain a comprehensive understanding of release properties. IVIVC reduces the need for costly in vivo studies and facilitates the establishment of meaningful dissolution specifications with significant cost savings and decreased regulatory burden. Furthermore, a meaningful IVIVC should predict Cmax and AUC within 20%, aligning with FDA guidance while adhering...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:25Strategies for Assessing and Addressing Confounding
Confounding is a critical issue in epidemiological studies, often leading to misleading conclusions about associations between exposures and outcomes. It occurs when the relationship between the exposure and the outcome is mixed with the effects of other factors that influence the outcome. Given that, addressing confounding is of high importance for drawing accurate inferences in research.
Confounding can be addressed at both the design phase of a study and through analytical methods after data...
Confounding can be addressed at both the design phase of a study and through analytical methods after data...